207 related articles for article (PubMed ID: 25384218)
1. RASAL2 activates RAC1 to promote triple-negative breast cancer progression.
Feng M; Bao Y; Li Z; Li J; Gong M; Lam S; Wang J; Marzese DM; Donovan N; Tan EY; Hoon DS; Yu Q
J Clin Invest; 2014 Dec; 124(12):5291-304. PubMed ID: 25384218
[TBL] [Abstract][Full Text] [Related]
2. miR-136 suppresses tumor invasion and metastasis by targeting RASAL2 in triple-negative breast cancer.
Yan M; Li X; Tong D; Han C; Zhao R; He Y; Jin X
Oncol Rep; 2016 Jul; 36(1):65-71. PubMed ID: 27108696
[TBL] [Abstract][Full Text] [Related]
3. RASAL2, a RAS GTPase-activating protein, inhibits stemness and epithelial-mesenchymal transition via MAPK/SOX2 pathway in bladder cancer.
Hui K; Gao Y; Huang J; Xu S; Wang B; Zeng J; Fan J; Wang X; Yue Y; Wu S; Hsieh JT; He D; Wu K
Cell Death Dis; 2017 Feb; 8(2):e2600. PubMed ID: 28182001
[TBL] [Abstract][Full Text] [Related]
4. The RasGAP gene, RASAL2, is a tumor and metastasis suppressor.
McLaughlin SK; Olsen SN; Dake B; De Raedt T; Lim E; Bronson RT; Beroukhim R; Polyak K; Brown M; Kuperwasser C; Cichowski K
Cancer Cell; 2013 Sep; 24(3):365-78. PubMed ID: 24029233
[TBL] [Abstract][Full Text] [Related]
5. Low Expression of Rasal2 Promotes Non-small Cell Lung Cancer Metastasis through Ras/ERK Pathway.
Fan D; Yu S; Yang Y; Qu S
Biol Pharm Bull; 2021; 44(7):992-998. PubMed ID: 34193694
[TBL] [Abstract][Full Text] [Related]
6. RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer.
Koh SB; Ross K; Isakoff SJ; Melkonjan N; He L; Matissek KJ; Schultz A; Mayer EL; Traina TA; Carey LA; Rugo HS; Liu MC; Stearns V; Langenbucher A; Saladi SV; Ramaswamy S; Lawrence MS; Ellisen LW
Clin Cancer Res; 2021 Sep; 27(17):4883-4897. PubMed ID: 34168046
[TBL] [Abstract][Full Text] [Related]
7. PRKAA/AMPKα phosphorylation switches the role of RASAL2 from a suppressor to an activator of autophagy.
Bao Y; Qian C; Liu MY; Jiang F; Jiang X; Liu H; Zhang Z; Sun F; Fu N; Hou Z; Ke Y; Li Y; Qian ZM
Autophagy; 2021 Nov; 17(11):3607-3621. PubMed ID: 33563064
[TBL] [Abstract][Full Text] [Related]
8. Phosphorylated Rasal2 facilitates breast cancer progression.
Wang X; Qian C; Yang Y; Liu MY; Ke Y; Qian ZM
EBioMedicine; 2019 Dec; 50():144-155. PubMed ID: 31759919
[TBL] [Abstract][Full Text] [Related]
9. RASAL2 down-regulation in ovarian cancer promotes epithelial-mesenchymal transition and metastasis.
Huang Y; Zhao M; Xu H; Wang K; Fu Z; Jiang Y; Yao Z
Oncotarget; 2014 Aug; 5(16):6734-45. PubMed ID: 25216515
[TBL] [Abstract][Full Text] [Related]
10. RASAL2 promotes lung cancer metastasis through epithelial-mesenchymal transition.
Li N; Li S
Biochem Biophys Res Commun; 2014 Dec; 455(3-4):358-62. PubMed ID: 25446096
[TBL] [Abstract][Full Text] [Related]
11. miR‑654‑3p suppresses cell viability and promotes apoptosis by targeting RASAL2 in non‑small‑cell lung cancer.
Xiong J; Xing S; Dong Z; Niu L; Xu Q; Li Y; Liu P; Yang P
Mol Med Rep; 2021 Feb; 23(2):. PubMed ID: 33300072
[TBL] [Abstract][Full Text] [Related]
12. Loss of RAB1B promotes triple-negative breast cancer metastasis by activating TGF-β/SMAD signaling.
Jiang HL; Sun HF; Gao SP; Li LD; Hu X; Wu J; Jin W
Oncotarget; 2015 Jun; 6(18):16352-65. PubMed ID: 25970785
[TBL] [Abstract][Full Text] [Related]
13. RASAL2 Plays Inconsistent Roles in Different Cancers.
Zhou B; Zhu W; Jiang X; Ren C
Front Oncol; 2019; 9():1235. PubMed ID: 31799194
[TBL] [Abstract][Full Text] [Related]
14. Rasal2 deficiency reduces adipogenesis and occurrence of obesity-related disorders.
Zhu X; Xie S; Xu T; Wu X; Han M
Mol Metab; 2017 Jun; 6(6):494-502. PubMed ID: 28580280
[TBL] [Abstract][Full Text] [Related]
15. Loss of RasGAP Tumor Suppressors Underlies the Aggressive Nature of Luminal B Breast Cancers.
Olsen SN; Wronski A; Castaño Z; Dake B; Malone C; De Raedt T; Enos M; DeRose YS; Zhou W; Guerra S; Loda M; Welm A; Partridge AH; McAllister SS; Kuperwasser C; Cichowski K
Cancer Discov; 2017 Feb; 7(2):202-217. PubMed ID: 27974415
[TBL] [Abstract][Full Text] [Related]
16. RASAL2 mediated the enhancement of YAP1/TIAM1 signaling promotes malignant phenotypes of pancreatic ductal adenocarcinoma.
Yue Y; Wu K; Qian W; Zhu Z; Zhang S; Zhang W; Zhang W; Wu S; Li L; Wu Z; Ma Q; Xie K; Wang Z
Int J Biol Sci; 2022; 18(10):4245-4259. PubMed ID: 35844783
[TBL] [Abstract][Full Text] [Related]
17. Epigenomic Inactivation of RasGAPs Activates RAS Signaling in a Subset of Luminal B Breast Cancers.
Sears R; Gray JW
Cancer Discov; 2017 Feb; 7(2):131-133. PubMed ID: 28167613
[TBL] [Abstract][Full Text] [Related]
18. Brain endothelial cells promote breast cancer cell extravasation to the brain via EGFR-DOCK4-RAC1 signalling.
Galloni C; Egnuni T; Zahed Mohajerani S; Ye J; Mittnacht S; Speirs V; Lorger M; Mavria G
Commun Biol; 2024 May; 7(1):602. PubMed ID: 38762624
[TBL] [Abstract][Full Text] [Related]
19. ARF1 controls Rac1 signaling to regulate migration of MDA-MB-231 invasive breast cancer cells.
Lewis-Saravalli S; Campbell S; Claing A
Cell Signal; 2013 Sep; 25(9):1813-9. PubMed ID: 23707487
[TBL] [Abstract][Full Text] [Related]
20. Activation of H-Ras and Rac1 correlates with epidermal growth factor-induced invasion in Hs578T and MDA-MB-231 breast carcinoma cells.
Koh MS; Moon A
Biochem Biophys Res Commun; 2011 Mar; 406(1):25-9. PubMed ID: 21281602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
